Research Article

Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and CEA as the Potential Prognostic Biomarkers for Colorectal Cancer

Fu Ming-Sheng, Du Mei-Ling, Cai Xun-Quan, Hu Yuan-Xin, Zhang Wei-Jie, and Pan Qin-Cong

Department of Gastroenterology, Shanghai Fifth People’s Hospital Fudan University, No. 801, Heqing Road, Minhang District, Shanghai 200240, China

Correspondence should be addressed to Fu Ming-Sheng; fumingsheng@fudan.edu.cn

Received 11 September 2021; Revised 27 November 2021; Accepted 4 December 2021; Published 4 January 2022

Academic Editor: Masanao Nakamura

Copyright © 2022 Fu Ming-Sheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. This study was to evaluate the prognostic value of the preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and carcinoembryonic antigen (CEA) in colorectal cancer (CRC) patients and to identify the potential and easily accessible prognostic biomarkers for CRC. Methods. We retrospectively reviewed altogether the records of 330 CRC patients according to inclusion criteria. The clinical characteristics include age at diagnosis, body mass index (BMI), preoperative CEA level, neutrophil, lymphocyte, and platelet count, tumor primary site and size, clinical pathological TNM stage, and survival status were recorded through the review of medical records. The overall survival (OS) was calculated using the Kaplan–Meier method. The Cox proportional hazards model was used for the univariate and multivariate analysis to evaluate the prognostic factors of CRC. Results. A total of 330 patients were finally included in the current study. The mean follow-up duration was 32.8 ± 19.1 months (range, 0.1–67.7). Compared with the median OS, preoperative high NLR, PLR, and CEA, and low BMI had lower median OS. The NLR and PLR value rise indicates lower median OS in stage I-II CRC; however, the NLR value and CEA level rise indicates lower median OS in stage III-IV CRC. Preoperative high NLR, PLR, and CEA level and low BMI have poorer OS by univariate analysis. By multivariate analysis, the age, sex, N, M stage, and BMI demonstrated independently influence the OS of CRC. NLR was an independent predictor of stage I-II CRC, and the CEA level was an independent predictor of stage III-IV CRC. Conclusions. Our results show that preoperative high NLR, PLR, CEA, and low BMI had poorer OS, NLR was an independent predictor of stage I-II CRC, and the CEA level was an independent predictor of stage III-IV CRC.

1. Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide, and the incidence of CRC in China is rising continuously in recent years; however, most of the patients were still diagnosed in the advanced stage leading to unsatisfactory prognosis for them [1]. The prognoses of CRC are mainly influenced by the completeness of surgical resection and the pathological stage [2–4]. Thus, it is urgent for us to identify the effective potential prognostic biomarkers for the survival improvement of CRC patients.

As we all know, systemic inflammatory response plays a vital role as a leading cause of the neoplastic process, and it was actively engaged in the genesis and propagation of various cancers [5, 6]. We know that systemic inflammation can be reflected by the parameters of peripheral blood including white blood cells, neutrophils, lymphocytes, and platelets. The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have been confirmed to be the prognosis indicators for many malignancies such as biliary tract cancer and gastric cancer [7, 8]. Systemic inflammation has been linked to poor prognosis of colorectal
cancer [9]. Recently, preoperative systemic inflammation indexes are considered as promising prognostic predictors which have easy accessibility and convenient application [10]. Elevated NLR and PLR have been associated with poor survival of colorectal cancer [11]. Carcinoembryonic antigen (CEA) is regarded as the common serological biomarker for the detection and monitoring of CRC but has insufficient sensitivity and specificity for prognostic [12].

Therefore, the aim of this study was to evaluate the prognostic values of preoperative NLR and PLR and CEA levels in CRC patients. In order to identify the potential and easily accessible prognostic biomarkers for CRC.

2. Materials and Methods

2.1. Patients. The retrospective analysis was conducted in patients with histologically confirmed colorectal adenocarcinoma who underwent surgical resection in the Department of Gastrointestinal Surgery at Shanghai Fifth People’s Hospital, Fudan University between January 1, 2015, and December 31, 2017. The exclusion criteria were (1) clinical confirmation of infectious disease or other diseases that caused systemic inflammation before surgery, (2) patients diagnosed with previous or concurrent malignancies, (3) patients with hematologic disorders, (4) patients with cirrhosis, and (5) patients who received steroid therapy. At last, 330 patients were enrolled in this study, and informed consent was obtained from all patients. This study was approved by the ethics committee of Shanghai Fifth People's Hospital, Fudan University.

2.2. Blood Samples and Reference Values. Blood samples were drawn from venous blood within 1 week before the date of surgery by a nurse. The blood samples are tested for complete blood count and the CEA value. The reference range of CEA value is 0.0–4.7 ng/mL, the reference range is (2.0–7.0) × 10^9/L for neutrophils count, (100–300) × 10^9/L for platelets count, and (0.80–4.0) × 10^9/L for lymphocytes count. The NLR and PLR were calculated by dividing the absolute number of neutrophils or platelets by the absolute number of lymphocytes, respectively.

2.3. Evaluation of Clinical Characteristics. The clinical characteristics of all colorectal cancer patients, including age at diagnosis, sex, body mass index (BMI), preoperative CEA level, neutrophil, lymphocyte, and platelet count, NLR, PLR, tumor primary site (rectum, colon), tumor size (diameter <5 cm, ≥5 cm), clinical pathological stage (stage I-II, stage III-IV), TNM stage (AJCC, version 7), and survival status (alive/died), were recorded through the review of medical records.

The overall survival (OS) time was measured from the date of surgery to the date of death from any cause or most recent follow-up. The survival and follow-up data were obtained by collecting outpatient clinical records or by directly contacting the patient or their relatives through a phone call from January 1, 2015, to June 30, 2020.

2.4. Statistical Analysis. The optimal cut-off values of preoperative NLR, PLR, BMI, and CEA were determined by the receiver operating characteristic (ROC) curve. Survival analysis was computed using the Kaplan–Meier method and compared by the log-rank test. The Cox proportional hazards model with a 95% confidence interval was used for the univariate analysis and multivariate analysis to assess the effect of patient characteristics and other significant prognostic factors. All statistical tests were two-sided, and associations were considered statistically significant at a nominal level of 0.05 (P < 0.05). Statistical analysis was performed using the SPSS software for windows (version 25.0).

3. Results

3.1. Baseline Clinical Characteristics of CRC Patients. A total of 330 patients were finally included in the current study, including 198 (60.0%) males and 132 (40.0%) females. The mean age was 71.7 ± 12.3 years (range, 32–99). The mean BMI was 21.7 ± 1.9 (range, 17.5–31.4). There was no statistical difference between the NLR (P = 0.382) and PLR (P = 0.232) in the high and low BMI groups. A total of 201 patients (60.9%) had colon cancer and the remaining 129 patients (39.1%) had rectal cancer. The evaluation of TNM stages revealed that the clinical pathological diagnoses were 163 patients of stage I-II and 167 patients of stage III-IV. The mean follow-up duration was 32.8 ± 19.1 months (range, 0.1–67.7).

3.2. NLR, PLR, BMI, and CEA Cut-Off Value. The ROC curve could calculate the sensitivity and specificity levels of NLR, PLR, BMI, and CEA as predictors of CRC survival. The optimal cut-off value of NLR was calculated as 3.03 with the areas under the curve (AUC) = 0.578 (P = 0.015), a sensitivity of 56.9%, a specificity of 63.2%, a specificity of 51.6%, and the BMI was 21.7 with AUC = 0.509 (P = 0.001), a sensitivity of 67.4%, a specificity of 68.8%, and the CEA was 13.4 with AUC = 0.573 (P = 0.022), a sensitivity of 35.4%, a specificity of 81.2%, by the AUC with the Youden index. All the patients were divided into high and low groups according to the NLR, PLR, BMI, and CEA cut-off values.

3.3. Kaplan–Meier Survival Analysis. The Kaplan–Meier estimates of overall survival according to main clinical variables status are shown in Tables 1–3 and Figures 1 and 2. Table 1 shows that the average survival month of colorectal cancer is significantly reduced in the high group of NLR, PLR, BMI, and CEA or the combination of all three. From Table 2 and Figure 2, we found that the NLR value rise in early and advanced colorectal cancer indicates a poor prognosis, and the PLR value rise in early colorectal cancer indicates a poor prognosis. On the contrary, the CEA level elevated in stage III-IV colorectal cancer indicates a poor prognosis. From
Table 1: Survival analysis using the Kaplan–Meier and compared by the log-rank test.

| Characteristics   | N     | Mean OS (months) | $X^2$ | P value |
|-------------------|-------|------------------|-------|---------|
| Age               |       |                  |       |         |
| <65 Y             | 87    | 51.5             | 8.3   | 0.004   |
| ≥65 Y             | 243   | 41.7             |       |         |
| Sex               |       |                  |       |         |
| Male              | 198   | 41               | 6.7   | 0.01    |
| Female            | 132   | 48.6             |       |         |
| Primary site      |       |                  |       |         |
| Rectum            | 129   | 47.4             | 2.1   | 0.144   |
| Colon             | 201   | 42.3             |       |         |
| Tumor size        |       |                  |       |         |
| <5 cm             | 205   | 44.1             | 0.1   | 0.829   |
| 5+ cm             | 125   | 45               |       |         |
| T stage           |       |                  |       |         |
| T0–T2             | 68    | 48.7             | 2.3   | 0.138   |
| T3–T4             | 262   | 43.2             |       |         |
| N stage           |       |                  |       |         |
| N0                | 185   | 48.5             | 8.9   | 0.003   |
| N1–N3             | 145   | 38.7             |       |         |
| M stage           |       |                  |       |         |
| M0                | 275   | 46.9             | 17.9  | <0.001  |
| M1                | 55    | 30.7             |       |         |
| Stage             |       |                  |       |         |
| I–II              | 163   | 49.2             | 9.1   | 0.003   |
| III–IV            | 167   | 39.2             |       |         |
| NLR               |       |                  |       |         |
| <3.03 (low)       | 176   | 49.7             | 16.6  | <0.001  |
| ≥3.03 (high)      | 154   | 37.4             |       |         |
| PLR               |       |                  |       |         |
| <149.73 (low)     | 148   | 49.2             | 9.7   | 0.002   |
| ≥149.73 (high)    | 182   | 40.2             |       |         |
| CEA (ng/mL)       |       |                  |       |         |
| <13.4 (low)       | 244   | 47.9             | 17.9  | <0.001  |
| ≥13.4 (high)      | 86    | 33.3             |       |         |
| CEA + NLR         |       |                  |       |         |
| Low               | 141   | 52.6             | 24.4  | <0.001  |
| High              | 189   | 37.4             |       |         |
| CEA + PLR         |       |                  |       |         |
| Low               | 117   | 51.6             | 13.4  | <0.001  |
| High              | 213   | 40.4             |       |         |
| NLR + PLR         |       |                  |       |         |
| Low               | 116   | 52               | 15.5  | <0.001  |
| High              | 214   | 40               |       |         |
| CEA + NLR + PLR   |       |                  |       |         |
| Low               | 94    | 54.7             | 19.3  | <0.001  |
| High              | 236   | 40.2             |       |         |
| BMI               |       |                  |       |         |
| <21.7 (low)       | 155   | 35.1             | 35.5  | <0.001  |
| ≥21.7 (high)      | 175   | 52.3             |       |         |

NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CEA, carcinoembryonic antigen; BMI, body mass index.

Table 2: Kaplan–Meier survival analysis and log-rank test compared in the clinical pathological stage.

| Characteristics     | Stage I–II | Stage III–IV |
|---------------------|------------|--------------|
|                     | N | Mean OS (months) | $X^2$ | P value | N | Mean OS (months) | $X^2$ | P value |
| NLR                 |   |                 |       |         |   |                 |       |         |
| Low                 | 94 | 54.2           | 10.7  | 0.001   | 82 | 43.9           | 4.9   | 0.027   |
| High                | 69 | 41.4           |       |         | 85 | 34             |       |         |
| PLR                 |   |                 |       |         |   |                 |       |         |
| Low                 | 80 | 54.1           | 7.4   | 0.007   | 68 | 42.9           | 2.2   | 0.139   |
| High                | 83 | 44.9           |       |         | 99 | 35.5           |       |         |
| CEA (ng/mL)         |   |                 |       |         |   |                 |       |         |
| Low                 | 140| 49.8           | 0.7   | 0.383   | 104| 44.9           | 12.4  | <0.001  |
| High                | 23 | 43.9           |       |         | 63 | 29.5           |       |         |
| CEA + NLR           |   |                 |       |         |   |                 |       |         |
| Low                 | 83 | 54.4           | 8.6   | 0.003   | 58 | 49.6           | 12.1  | 0.001   |
| High                | 80 | 42.9           |       |         | 109| 33.2           |       |         |
| CEA + PLR           |   |                 |       |         |   |                 |       |         |
| Low                 | 71 | 53.7           | 5.2   | 0.023   | 46 | 47.4           | 5.6   | 0.018   |
| High                | 92 | 45.9           |       |         | 121| 35.4           |       |         |
| NLR + PLR           |   |                 |       |         |   |                 |       |         |
| Low                 | 64 | 56.2           | 9.9   | 0.002   | 52 | 46.2           | 4.9   | 0.027   |
| High                | 99 | 44.7           |       |         | 115| 35.3           |       |         |
| CEA + NLR + PLR     |   |                 |       |         |   |                 |       |         |
| Low                 | 58 | 55.6           | 7.2   | 0.007   | 36 | 52.4           | 9.5   | 0.002   |
| High                | 105| 45.6           |       |         | 131| 35             |       |         |
Table 3: Kaplan–Meier survival analysis and log-rank test compared in the primary site.

| Characteristics | Rectum | Colon |
|-----------------|--------|-------|
|                 | N      | Mean OS (months) | X² | P value | N     | Mean OS (months) | X² | P value |
| NLR Low         | 80     | 51.4            | 6.5 | 0.011   | 96    | 48.1            | 8.5 | 0.004   |
| NLR High        | 49     | 39.5            |     |         | 105   | 36.3            |     |         |
| PLR Low         | 71     | 48.5            | 1.4 | 0.234   | 77    | 48.9            | 7.3 | 0.007   |
| PLR High        | 58     | 44.9            |     |         | 124   | 37.5            |     |         |
| CEA (ng/mL) Low | 106    | 49.7            | 4.9 | 0.027   | 138   | 46.5            | 11.8| 0.001   |
| CEA (ng/mL) High| 23     | 35.4            |     |         | 63    | 32.1            |     |         |
| CEA + NLR Low   | 69     | 52.4            | 6.3 | 0.012   | 72    | 52.8            | 16.9| <0.001  |
| CEA + NLR High  | 60     | 40.9            |     |         | 129   | 35.4            |     |         |
| CEA + PLR Low   | 59     | 50.7            | 3.6 | 0.057   | 58    | 51.2            | 8.7 | 0.003   |
| CEA + PLR High  | 70     | 43.8            |     |         | 143   | 37.9            |     |         |
| NLR + PLR Low   | 59     | 48.4            | 1.9 | 0.164   | 57    | 53.4            | 13.6| <0.001  |
| NLR + PLR High  | 70     | 44.8            |     |         | 144   | 37.2            |     |         |
| CEA + NLR + PLR Low | 49 | 49.8            | 2.8 | 0.096   | 45    | 57.7            | 17.6| <0.001  |
| CEA + NLR + PLR High | 80 | 44.7            |     |         | 156   | 37.1            |     |         |

Table 3, we found that the NLR and CEA elevated in rectum and colon cancer indicates a poor prognosis, and the PLR value rise only in colon cancer indicates a poor prognosis.

3.4. Univariate and Multivariate Analysis. For analysis of all variables in prognostic factors, Tables 4–6 show the results of univariate and multivariate analysis of various parameters with OS evaluated in our study.

Our results showed that the CRC patients with preoperative high NLR, PLR, and CEA levels, and the low BMI group have poorer OS in the univariate analysis. The group of over 65 years of age and the group of male patients had a poor prognosis as shown in Table 4. However, there were no significant associations with OS in the primary site, tumor size, and T-stage groups with univariate analysis (Table 4).

Multivariate analysis was performed to assess the independent predictors for survival. As shown in Table 5, the risk of death in the high NLR group was 1.38 times that of the low NLR group (P = 0.112), the high PLR group was 1.28 times that of the low PLR group (P = 0.226), the high BMI group was 0.26 times that of the low BMI group (P < 0.001), and the high CEA group was 1.24 times that of the low CEA group (P = 0.268). The results show that age, sex, N, M stage, and BMI demonstrated independently the influence OS of CRC. In addition, when we conducted the study by stage, we found that NLR was an independent predictor of stage I-II colorectal cancer prognosis, and the CEA level was an independent predictor of stage III-IV colorectal cancer prognosis (Table 6).

4. Discussion

Various studies confirmed that inflammatory response plays an important role in the progression of tumor microenvironment, some changes of inflammatory cells might be a predictor for prognosis, and changes of immune cellular components in peripheral venous blood could reflect tumor inflammation status for predicting survival prognosis [13]. Since complete blood count and CEA level are routinely measured as part of the preoperative work-up of patients undergoing surgery, their possible prognostic value could be very relevant in clinical practice.

The roles of lymphocytes in tumor immune surveillance and immunoediting have been widely studied [14]. Lymphocytes can eliminate tumor cells through the cytotoxic effects [15]. On the contrary, neutrophils and monocytes may contribute to tumor progression. Neutrophils release prostaglandin E2 (PGE2) to amplify inflammation and create a tumor microenvironment, which can promote colon tumorigenesis, suppress activities of natural killer cells, and increase the exudation of tumor cells through the secretion of interleukin-1β (IL-1β) and matrix metalloproteinases (MMP) [16]. Besides, neutrophils can release neutrophil extracellular traps to promote hepatic metastasis of CRC by trapping tumor cells [17]. Therefore, NLR is an integrated indicator for the pro-tumor effect of neutrophils and the antitumor immunity of lymphocytes. It has been demonstrated that high levels of platelets are capable of promoting cancer progression by increasing angiogenesis through the production of the vascular endothelial growth factor (VEGF), overexpression of which has been associated with disease progression and metastasis in patients with CRC [18]. In addition, platelets could secrete cellular growth factors such as platelet-derived growth factor, vascular endothelial growth factor, transforming growth factor-beta, and platelet factor 4 and then stimulate tumor angiogenesis and growth [19]. Therefore, elevated preoperative platelet counts probably signify an organic microenvironment conducive to tumor growth. PLR can reflect the balance between the cancer promotion capacity of platelet and the anti-tumor immunity of lymphocytes. CEA is mainly used for assistant diagnosis of malignant tumors, determining prognosis, and monitoring curative effect and recurrence of tumors, and it is most effective when patients have high preoperative serum CEA levels [20]. However, sensitivity is far from being sufficient [21]. Plasma CEA level is not consistently elevated in CRC and may be undetectable.
or present at only low levels with a poorly differentiated tumor [22].

Our results showed that the patients of preoperative high NLR, PLR, and CEA level had poorer OS by the Kaplan–Meier analysis. Similarly, the results showed that the OS of the high group was significantly reduced in the CEA combined with NLR or PLR, and the NLR combined with PLR. In addition, the OS of CRC patients who were male, over 65 years of age, had lymph node invasion, and had distant metastasis was poor. Furthermore, through the clinical pathological stage grouping analysis, in the stage I-II, the mean OS of high NLR and PLR was significantly reduced, but there is no statistical difference in OS in the CEA high and low groups. While, in the stage III-IV, the mean OS of high NLR, CEA was significantly reduced, and there was no statistical difference in OS between PLR high and low groups. When we grouped by primary site and analyzed, we found that the mean OS of high NLR, PLR, CEA was significantly reduced. The univariate Cox proportional hazards model

![Kaplan–Meier estimates of overall survival (OS) according to the main clinical variables status](image-url)
The multivariate Cox proportional hazards model analysis result showed that the age over 65, being male, N1–N2, M1 stage, and low BMI were independent risk factors for poor prognosis of CRC, without stratified analysis, NLR, PLR, and CEA level cannot be determined as independent risk factors for the prognosis of CRC. However, it was interesting that we found that high NLR value was independent risk factors for poor prognosis in Stage I-II group patients with CRC by stage conducted stratified, while in stage III-IV CRC patients, only a high CEA level was independent risk factor for poor prognosis. Our results showed that NLR to be predictive of outcome in CRC patients with stage I-II but not stage III-IV. We speculate that it may be related to the early inflammation and immune of CRC. Similarly, CEA is an independent predictor for advanced CRC (stage III-IV) but not stage I-II, which may be related to the release of higher levels of CEA in advanced CRC. Li [23] reported 5336 patients with CRC; the result showed that H-NLR was an independent prognostic factor for OS at multivariate analysis. Haram’s study concluded that preoperative NLR > 5 was associated with poorer OS in patients with CRC, they conducted a systematic review to assess the prognostic role of NLR in metastatic and non-

Figure 2: Kaplan–Meier estimates of overall survival (OS) according to the NLR, PLR, and CEA. (a) according to NLR (P < 0.001), (b) according to NLR in stage I-II (P = 0.001), (c) according to NLR in stage III-IV (P = 0.027), (d) according to PLR (P = 0.002), (e) according to PLR in stage I-II (P = 0.007), (f) according to PLR in stage III-IV (P = 0.139), (g) according to CEA (P < 0.001), (h) according to CEA in stage I-II (P = 0.383), (i) according to NLR in stage III-IV (P < 0.001).
metastatic CRC [24]. Zhou [25] reported postoperative inflammation indexes such as neutrophil and monocyte to lymphocyte ratio (NMLR), systemic immune inflammation index (SII), and C-reaction protein (CRP) to albumin (ALB) ratio (CAR) are promising prognostic predictors of CRC patients. Malietzis [26] reported 506 patients with non-metastatic CRC who did not receive adjuvant chemotherapy; the result showed that an independent prognostic role of H-NLR (>[3]) was not identified.

Furthermore, because of the difference in treatment and prognosis of the colon and rectal cancer, most of the studies included colon as well as rectal cancer, therefore producing results that may be biased [27]. The PLR has been demonstrated as a prognostic factor in gastric cancer [28] and esophageal carcinoma [29]. Previous research has demonstrated that the platelet addition to tumor cells can impede natural killer cell-mediated recognition and elimination of tumor cells, which may prime the tumor cells for metastasis [30]. In addition, NLR and PLR are related to non-neoplastic diseases, such as alcoholic liver cirrhosis (ALC) and nonalcoholic fatty liver disease (NAFLD). They are closely related to indirect and direct markers of liver fibrosis. Moreover, the NLR and PLR seem to correlate with a clinical progression of liver cirrhosis [31]. Milovanovic’s [32] study demonstrates that patients with NAFLD have a significant increase in the values of platelet indices (PCT), mean platelet volume (MPV), and platelet distribution width (PDW) when compared to the healthy controls. El-Gazzar’s [33] report showed that the NLR and PLR increased in stable COPD patients and further increased during exacerbation that can predict in-hospital mortality. Gasparyan [34] reported that the PLR and NLR have high predictive value in rheumatic diseases with predominantly neutrophilic inflammation. Li’s [35] study has shown that the NLR and PLR are the independent factors that affect the disease activity of rheumatoid arthritis patients and can better evaluate the disease activity and efficacy of rheumatoid arthritis. Our results show that the low BMI in CRC has a poor prognosis. Jaspan [36] reported that obese and underweight BMI are associated with increased CRC-specific and overall mortality compared to that of normal BMI. Long-term prognosis was similar for patients with obese and underweight BMI. The previous report showed that the mGPS and CEA accurately predict OS in patients with liver metastasis from CRC [37].

The main limitation of our study relates to its retrospective nature and the limited sample size. However, our study also has many strengths. First, all the patients have complete follow-up data after surgery. Second, we find some potential prognostic markers through stratified analysis.

| Table 4: Univariate analysis of overall survival by the Cox proportional hazards model. |
|-----------------|-----|------------|-----------|-----|
| Characteristics | N   | HR         | 95% CI    | P  |
| Age             |     |            |           |    |
| <65 Y           | 87  | REF        | 1.21–2.82 | 0.005 |
| ≥65 Y           | 243 | 1.84       |           |    |
| Sex             |     |            |           |    |
| Male            | 198 | REF        | 0.45–0.90 | 0.011 |
| Female          | 132 | 0.64       |           |    |
| Primary site    |     |            |           |    |
| Rectum          | 129 | REF        | 0.91–1.81 | 0.149 |
| Colon           | 201 | 1.29       |           |    |
| Tumor size      |     |            |           |    |
| <5 cm           | 205 | REF        | 0.69–1.35 | 0.83  |
| ≥5 cm           | 125 | 0.96       |           |    |
| T stage         |     |            |           |    |
| T0–T2           | 68  | 1.39       | 0.90–2.14 | 0.138 |
| T3–T4           | 262 |            |           |    |
| N stage         |     |            |           |    |
| N0              | 185 | REF        | 1.18–2.26 | 0.003 |
| N1–N3           | 145 | 1.63       |           |    |
| M stage         |     |            |           |    |
| M0              | 275 | REF        | 1.52–3.30 | <0.001 |
| M1              | 55  | 2.24       |           |    |
| Stage           |     |            |           |    |
| I-II            | 163 | REF        | 1.19–2.30 | 0.003 |
| III-IV          | 167 | 1.65       |           |    |
| NLR             |     |            |           |    |
| Low             | 176 | REF        | 1.41–2.73 | <0.001 |
| High            | 154 | 1.96       |           |    |
| PLR             |     |            |           |    |
| Low             | 148 | REF        | 1.21–2.40 | 0.002 |
| High            | 182 | 1.70       |           |    |
| CEA (ng/mL)     |     |            |           |    |
| Low             | 244 | REF        | 1.46–2.89 | <0.001 |
| High            | 86  | 2.05       |           |    |
| CEA + NLR       |     |            |           |    |
| Low             | 141 | REF        | 1.67–3.42 | <0.001 |
| High            | 189 | 2.39       |           |    |
| CEA + PLR       |     |            |           |    |
| Low             | 117 | REF        | 1.36–2.90 | <0.001 |
| High            | 213 | 1.99       |           |    |
| NLR + PLR       |     |            |           |    |
| Low             | 116 | REF        | 1.44–3.09 | <0.001 |
| High            | 214 | 2.11       |           |    |
| CEA + NLR + PLR |     |            |           |    |
| Low             | 94  | REF        | 1.65–3.99 | <0.001 |
| High            | 236 | 2.57       |           |    |
| BMI             |     |            |           |    |
| Low             | 155 | REF        | 0.26–0.52 | <0.001 |
| High            | 175 | 0.36       |           |    |

| Table 5: Multivariate analysis of overall survival by the Cox proportional hazards model. |
|-----------------|-----|------------|-----------|-----|
| Characteristics | N   | HR         | 95% CI    | P  |
| Age             |     |            |           |    |
| <65 Y           | 87  | REF        | 0.99–2.38 | 0.053 |
| ≥65 Y           | 243 | 1.54       |           |    |
| Sex             |     |            |           |    |
| Male            | 198 | REF        | 0.26–0.56 | <0.001 |
| Female          | 132 | 0.38       |           |    |
| Primary site    |     |            |           |    |
| Rectum          | 129 | REF        | 0.90–1.88 | 0.158 |
| Colon           | 201 | 1.30       |           |    |
| Tumor size      |     |            |           |    |
| <5 cm           | 205 | REF        | 0.62–1.34 | 0.639 |
| ≥5 cm           | 125 | 0.91       |           |    |
| T stage         |     |            |           |    |
| T0–T2           | 68  | REF        | 0.44–1.23 | 0.248 |
| T3–T4           | 262 | 0.74       |           |    |
| N stage         |     |            |           |    |
| N0              | 185 | REF        | 1.10–2.92 | 0.02 |
| N1–N3           | 145 | 1.79       |           |    |
| M stage         |     |            |           |    |
| M0              | 275 | REF        | 1.05–2.74 | 0.03 |
| M1              | 55  | 1.70       |           |    |
| Stage           |     |            |           |    |
| I-II            | 163 | REF        | 0.49–1.41 | 0.499 |
| III-IV          | 167 | 0.83       |           |    |
| NLR             |     |            |           |    |
| Low             | 176 | REF        | 0.92–2.06 | 0.112 |
| High            | 154 | 1.38       |           |    |
| PLR             |     |            |           |    |
| Low             | 148 | REF        | 0.86–1.91 | 0.226 |
| High            | 182 | 1.28       |           |    |
| CEA (ng/mL)     |     |            |           |    |
| Low             | 244 | REF        | 0.85–1.81 | 0.268 |
| High            | 86  | 1.24       |           |    |
| BMI             |     |            |           |    |
| Low             | 155 | REF        | 0.18–0.39 | <0.001 |
| High            | 175 | 0.26       |           |    |
5. Conclusion

In summary, whether it is a univariate or multivariate analysis, preoperative low BMI is a risk factor for poor prognosis of CRC. The preoperative high CEA level is an independent risk factor for poor prognosis in stage III-IV CRC patients. Besides, high NLR significantly affects survival in stage I-II CRC patients; it is an independent risk factor for poor prognosis in stage I-II CRC patients. In order to confirm our observations and identify the effective clinical survival value of NLR, PLR, and CEA, a higher number of cases are required for further studies in the future.

Data Availability

The data used to support the findings of this study are included in the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

FU conceived the study. Yx HU and Wj ZHANG collected clinical records and follow-up data of all colorectal cancer patients. MI DU conducted the Kaplan–Meier analysis. Xq CAI conducted the univariate and multivariate analysis. FU wrote the manuscript. FU revised the manuscript for important intellectual content. Qc PAN supervised the study.

Acknowledgments

This study was supported by the Shanghai Fifth People’s Hospital Scientific Research Project Fund (No.2020WYZT04) and Natural Science Research Funds of Minhang District, Shanghai (No. 2021MHZ091).

References

[1] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.
[2] S. Poornakala and N. Prema, “A study of morphological prognostic factors in colorectal cancer and survival analysis,” Indian Journal of Pathology & Microbiology, vol. 62, no. 1, pp. 36–42, 2019.
[3] Z. Chi, Z. Li, L. Cheng, and C. Wang, “Comparison of long-term outcomes after laparoscopic-assisted and open colectomy for splenic flexure cancer,” Journal of BUON: Official Journal of the Balkan Union of Oncology, vol. 23, no. 2, pp. 322–328, 2018.
[4] B. V. Micu, Ş. C. Vesa, T. R. Pop, and C. M. Micu, “Evaluation of prognostic factors for 5 year-survival after surgery for colorectal cancer,” Annali Italiani di Chirurgia, vol. 91, pp. 41–48, 2020.
[5] G. Marelli, A. Sica, L. Vannucci, and P. Allavena, “Inflammation as target in cancer therapy,” Current Opinion in Pharmacology, vol. 35, pp. 57–65, 2017.
[6] C. Lucas, N. Barnich, and H. Nguyen, “Microbiota, inflammation and colorectal cancer,” International Journal of Molecular Sciences, vol. 18, no. 6, p. 1310, 2017.
[7] K.-M. Cho, H. Park, D.-Y. Oh et al., “Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate

| Characteristics | Stage I-II | Stage III-IV |
|-----------------|-----------|-------------|
|                | HR        | 95% CI      | P value | HR        | 95% CI      | P value |
| Age <65 Y      | REF 1.63  | 0.83–3.19   | 0.156   | REF 1.91  | 1.08–3.40   | 0.027   |
| ≥65 Y          |           |             |         |           |             |         |
| Sex Male       | REF 0.66  | 0.39–1.15   | 0.141   | REF 0.62  | 0.37–1.03   | 0.064   |
|                | Female    |             |         |           |             |         |
| Primary site   | Rectum    | REF 1.19    | 0.68–2.06 | 0.546 | REF 1.04    | 0.64–1.69 | 0.881   |
|                | Colon     |             |         |         |             |         |
| Tumor size     | <5 cm     | REF 0.71    | 0.38–1.33 | 0.279 | REF 1.02    | 0.61–1.69 | 0.945   |
|                | 5+ cm     |             |         |         |             |         |
| T stage        | T0–T2     | REF 0.89    | 0.45–1.76 | 0.744 | REF 0.74    | 0.31–1.77 | 0.499   |
|                | T3–T4     |             |         |         |             |         |
| N stage        | N0        | REF 1.14    | 0.45–2.93 | 0.775 | REF 1.32    | 0.73–2.38 | 0.354   |
|                | N1–N3     |             |         |         |             |         |
| M stage        | M0        | REF 17.79   | 1.71–184.99 | 0.016 | REF 1.68    | 0.99–2.81 | 0.052   |
|                | M1        |             |         |         |             |         |
| NLR Low        | REF 2.06  | 1.14–3.75   | 0.017   | REF 1.04  | 0.61–1.77   | 0.891   |
|                | High      |             |         |         |             |         |
| PLR Low        | REF 1.67  | 0.89–3.14   | 0.108   | REF 1.33  | 0.79–2.25   | 0.290   |
|                | High      |             |         |         |             |         |
| CEA (ng/mL)    | Low       | REF 1.42    | 0.69–2.91 | 0.342 | REF 1.79    | 1.13–2.85 | 0.013   |
|                | High      |             |         |         |             |         |
prognosis of advanced biliary tract cancer,” Oncotarget, vol. 8, no. 2, pp. 2239–2341, 2017.

[8] L. Chen, Y. Zuo, L. Zhu et al., “Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy,” Oncotargets and Therapy, vol. 10, pp. 2569–2580, 2017.

[9] C. S. Roxburgh and D. C. McMillan, “Role of systemic inflammatory response in predicting survival in patients with primary operable cancer,” Future Oncology, vol. 6, no. 1, pp. 149–163, 2010.

[10] J. H. Park, D. G. Watt, C. S. D. Roxburgh, P. G. Horgan, and D. C. McMillan, “Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host,” Annals of Surgery, vol. 263, no. 2, pp. 326–336, 2016.

[11] Z.-Y. Zou, H.-L. Liu, N. Ning, S.-Y. Li, X.-H. Du, and R. Li, “Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer,” Oncology Letters, vol. 11, no. 3, pp. 2243–2248, 2016.

[12] E. McKeown, D. W. Nelson, E. K. Johnson et al., “Current approaches and challenges for monitoring treatment response in colon and rectal cancer,” Journal of Cancer, vol. 5, no. 1, pp. 31–43, 2014.

[13] F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001.

[14] G. P. Dunn, L. J. Old, and R. D. Schreiber, “The immunobiology of cancer immunosurveillance and immunomodulation,” Immunity, vol. 21, no. 2, pp. 137–148, 2004.

[15] L. V. Tito, J. R. Monson, and J. Greenman, “The role of CD8+ T cells in immune responses to colorectal cancer,” Cancer Immunology, Immunotherapy, vol. 51, no. 5, pp. 235–247, 2002.

[16] A. Spiegel, M. W. Brooks, S. Houshyar et al., “Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells,” Cancer Discovery, vol. 6, no. 6, pp. 630–649, 2016.

[17] J. Cools-Lariague, J. Spicer, B. McDonald et al., “Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis,” Journal of Clinical Investigation, vol. 123, no. 8, pp. 3446–3458, 2013.

[18] L. J. Gay and B. Felding-Habermann, “Contribution of platelets to tumour metastasis,” Nature Reviews Cancer, vol. 11, no. 2, pp. 123–134, 2011.

[19] W. He, C. Yin, G. Guo et al., “Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer,” Medical Oncology, vol. 30, no. 1, p. 439, 2013.

[20] M. J. Duffy, A. van Dalen, C. Haglund et al., “Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use,” European Journal of Cancer, vol. 43, no. 9, pp. 1348–1360, 2007.

[21] G. Saito, S. Sadahiro, H. Kamata et al., “Monitoring of serum carcinoembryonic antigen levels after curative resection of colon cancer: cutoff values determined according to preoperative factors enhance the diagnostic accuracy for recurrence,” Oncology, vol. 92, no. 5, pp. 276–282, 2017.

[22] I. J. Park, G.-S. Choi, K. H. Lim, B. M. Kang, and S. H. Jun, “Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level,” Annals of Surgical Oncology, vol. 16, no. 11, pp. 3087–3093, 2009.

[23] Y. Li, H. Jia, W. Yu et al., “Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection,” International Journal of Cancer, vol. 139, no. 1, pp. 220–231, 2016.

[24] A. Haram, M. R. Boland, M. E. Kelly, J. C. Bolger, R. M. Waldron, and M. J. Kerin, “The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review,” Journal of Surgical Oncology, vol. 115, no. 4, pp. 470–479, 2017.

[25] Z.-q. Zhou, S. Pang, X.-c. Yu et al., “Predictive values of postoperative and dynamic changes of inflammation indexes in survival of patients with resected colorectal cancer,” Current Medical Science, vol. 38, no. 5, pp. 798–808, 2018.

[26] G. Malietzis, M. Giaconetti, A. Askari et al., “A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery,” Annals of Surgery, vol. 260, no. 2, pp. 287–292, 2014.

[27] Y. Wu, C. Li, J. Zhao et al., “Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis,” World Journal of Surgical Oncology, vol. 14, no. 1, p. 289, 2016.

[28] G. Zhao, N. Liu, S. Wang et al., “Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer,” Medicine (Baltimore), vol. 99, no. 10, Article ID e19405, 2020.

[29] Y.-F. He, H.-Q. Luo, W. Wang et al., “Preoperative NLR and PLR in the middle or lower ESCC patients with radical operation,” European Journal of Cancer Care, vol. 26, no. 2, Article ID e12445, 2017.

[30] M. Labelle, S. Begum, and R. O. Hynes, “Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis,” Cancer Cell, vol. 20, no. 5, pp. 576–590, 2011.

[31] A. Michalak, H. Cichoż-Lach, M. Guz et al., “Towards an evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients with hematological scales,” World Journal of Gastroenterology, vol. 26, no. 47, pp. 7538–7549, 2020.

[32] T. Milovanovic Alempijevic, M. Stojkovic Lalosevic, I. Dumic et al., “Diagnostic accuracy of platelet count and platelet indices in noninvasive assessment of fibrosis in nonalcoholic fatty liver disease patients,” Canadian Journal of Gastroenterology and Hepatology, vol. 2017, Article ID 6070135, 5 pages, 2017.

[33] A. G. El-Gazzar, M. H. Kamel, O. K. M. Elbahnasy, and M. E.-S. El-Naggar, “Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients,” Expert Review of Respiratory Medicine, vol. 14, no. 1, pp. 111–116, 2020.

[34] A. Y. Gaspyryan, L. Ayyazyan, U. Mukanova, M. Yessirkepov, and G. D. Kitas, “The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases,” Annals of Laboratory Medicine, vol. 39, no. 4, pp. 345–357, 2019.

[35] M. Li and L. Xie, “Correlation between NLR, PLR, and LMR and disease activity,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 4433141, 6 pages, 2021.

[36] V. Jaspan, K. Lin, and V. Popov, “The impact of anthropometric parameters on colorectal cancer prognosis: a systematic review and meta-analysis,” Critical Reviews in Oncology, vol. 159, Article ID 103232, 2021.